WellTheory
Overview
WellTheory is a healthcare company focused on providing whole-person care for autoimmune disease patients. Based in San Francisco, California, WellTheory was founded in 2022 by Ellen Rudolph, Claire, and Wallace, who have personal experiences with autoimmune conditions. The company raised $14 million in Series A funding in October 2025, led by General Catalyst, bringing its total financing to $26.2 million. It builds on a collaborative care model that integrates lifestyle and dietary interventions with medical treatment, emphasizing personalized, proactive healthcare.
Recent Developments
- October 2025: WellTheory announced the completion of a $14 million Series A funding round led by General Catalyst, with participation from key investors such as 7wire Ventures, Ingeborg Investments, Accel, and others. This funding is intended to advance the development of AI tools and expand partnerships with major employers and health plans.
- May 2025: The company raised an additional $5 million to launch new AI-based tools for autoimmune care. This investment came from new investors including Samsung Next and Opal Ventures, indicating growing interest in WellTheory's healthcare model.
- Expansion and Partnerships: Over the last year, WellTheory reported 10× growth in its membership and 5× growth in its revenue. It secured partnerships with Fortune 100 and 500 companies, as well as health plans like Sentara Health Plans.
- AI-Powered Tools: WellTheory introduced 'Care Hub' and 'Care Scribe', AI tools designed to personalize care by aggregating data and creating tailored care plans. These tools are fully integrated into their operational framework to improve patient outcomes and reduce costs.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2022 |
| Headquarters | San Francisco, California, USA |
| Founders | Ellen Rudolph, Claire, Wallace |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | General Catalyst, 7wire Ventures, Accel, etc. |
| Industry | Healthcare |
| Number of Employees | Not publicly disclosed |
Early History
WellTheory was founded out of the personal struggles and experiences of its founders with autoimmune diseases. Ellen Rudolph and co-founders Claire and Wallace each had firsthand experiences with the gaps in conventional autoimmune care. This personal connection to the mission drove them to establish WellTheory in 2022, aiming to create a more holistic and person-centered approach to treating autoimmune conditions. Initially operating within a private beta, WellTheory addressed a significant unmet need within the healthcare system, focusing on diet, lifestyle, and providing personalized care through a digital platform.
Company Profile and Achievements
WellTheory employs a unique business model that combines high-touch care with AI-enabled personalization. Since its inception, WellTheory has prioritized the development of its proprietary platform, which centers around evidence-based interventions such as nutritional guidance, stress management, sleep hygiene, and emotional well-being.
- 2022: Company founded by Ellen Rudolph, Claire, and Wallace.
- 2024: Launched commercially and partnered with women's health unicorn Maven Clinic, achieving a notable increase in adoption and subsequent scaling efforts.
- 2025: Secured $14 million in Series A funding and expanded its offerings to Fortune 500 companies and health plans. Developed and implemented AI-driven tools like Care Scribe to improve operational efficiencies.
Current Operations and Market Position
Today, WellTheory serves as a forefront leader in autoimmune care by leveraging AI technology to offer personalized, whole-person treatment. Their model has shown significant improvements in reducing healthcare costs for employers while enhancing patient outcomes. WellTheory's strategy targets integrating holistic medical treatment with lifestyle modifications, a desirable approach in today's healthcare industry where autoimmune diseases have been growing rapidly.
Conclusion
WellTheory stands out in the healthcare sector by reimagining the way autoimmune diseases are treated, emphasizing a patient-centered approach that considers broader lifestyle factors. As they continue to expand their services and refine their AI capabilities, WellTheory is poised to impact significantly the management of autoimmune diseases at scale, providing not only superior patient outcomes but also economic benefits for employers and health plans alike. With an aggressive strategy focused on partnerships and technological enhancement, WellTheory is well-positioned to lead the charge in transforming autoimmune care.